Oracle Corporation (NYSE:ORCL) announced on Thursday that it is working with the National Institutes of Health (NIH) to support COVID-19 vaccine trials.
The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, recently established the COVID-19 Prevention Network (CoVPN). Its goal is to register millions of volunteers for large-scale clinical testing of vaccines and monoclonal antibodies intended to protect people from COVID-19.
As part of this initiative, Oracle has developed a cloud system called the CoVPN Volunteer Screening Registry to identify and screen volunteers who want to participate in COVID-19 clinical trials. More than 100,000 people have registered since the system went live a week ago.
The program is expected to support hundreds of clinical trial sites across the United States and internationally by the end of the year, Oracle said.
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
ALK partners with GenSci to expand allergy immunotherapy market in China
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Celltrion's OMLYCLO receives US FDA approval
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy